Furthermore, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been suggested to decrease the risk of exudative AMD (15), while sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit a robust protective effect against macular degeneration in diabetic patients (16). This evidence concerns the gene SLC5A2 and age-related macular degeneration.